Feasibility and reliability of evaluate PD‐L1 expression determination using small biopsy specimens in non‐small cell lung cancer
Abstract Background Programmed cell death ligand‐1 (PD‐L1) is a useful biomarker in non‐small cell lung cancer (NSCLC) patients who would probably benefit from immunotherapy. In most patients with advanced stage NSCLC, only small biopsy specimens were available for the evaluation of PD‐L1 expression...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-09-01
|
Series: | Thoracic Cancer |
Subjects: | |
Online Access: | https://doi.org/10.1111/1759-7714.14075 |
id |
doaj-4a5de19f92c948f0b9e6420b23e9257f |
---|---|
record_format |
Article |
spelling |
doaj-4a5de19f92c948f0b9e6420b23e9257f2021-09-02T01:52:16ZengWileyThoracic Cancer1759-77061759-77142021-09-0112172339234410.1111/1759-7714.14075Feasibility and reliability of evaluate PD‐L1 expression determination using small biopsy specimens in non‐small cell lung cancerMinjiang Chen0Yan Xu1Jing Zhao2Ji Li3Xiangning Liu4Wei Zhong5Mengzhao Wang6Department of Respiratory and Critical Care Medicine Peking Union Medical College Hospital Beijing ChinaDepartment of Respiratory and Critical Care Medicine Peking Union Medical College Hospital Beijing ChinaDepartment of Respiratory and Critical Care Medicine Peking Union Medical College Hospital Beijing ChinaDepartment of Pathology Peking Union Medical College Hospital Beijing ChinaDepartment of Respiratory and Critical Care Medicine Peking Union Medical College Hospital Beijing ChinaDepartment of Respiratory and Critical Care Medicine Peking Union Medical College Hospital Beijing ChinaDepartment of Respiratory and Critical Care Medicine Peking Union Medical College Hospital Beijing ChinaAbstract Background Programmed cell death ligand‐1 (PD‐L1) is a useful biomarker in non‐small cell lung cancer (NSCLC) patients who would probably benefit from immunotherapy. In most patients with advanced stage NSCLC, only small biopsy specimens were available for the evaluation of PD‐L1 expression. In this study, we evaluated the feasibility and reliability of PD‐L1 testing on small biopsy samples. Methods Small specimens of advanced NSCLC patients obtained via endobronchial ultrasound‐guided transbronchial needle aspiration (EBUS‐TBNA), endobronchial biopsy (EBB), or computed tomography (CT)‐guided core‐needle biopsy were collected. Tumor cell count and tissue sufficiency for PD‐L1 immunohistochemistry (IHC) were evaluated and compared. The clinical course of patients who received immunotherapy in the study population was also examined. Results Tissue acquisitions for PD‐L1 testing in three groups were all above 90%, with no statistically significant differences. The PD‐L1 expressions levels were concordant in most patients with more than one sample (8/11). In the EBB group, PD‐L1‐positive patients had higher objective response rate (ORR) (53.2% vs. 26.9%, p = 0.048) and longer progression‐free survival (PFS) (312 vs. 179 days, p = 0.035) than PD‐L1 negative patients. In the core needle biopsy group, patients with positive PD‐L1 expression also trended to have higher ORR and longer PFS. However, in the EBUS‐TBNA group, both ORR and PFS were similar between patients with positive or negative PD‐L1 expression. Conclusions This study showed that EBUS‐TBNA, EBB, and core needle biopsy provides adequate samples for PD‐L1 testing. The predictive value of PD‐L1 expression on different small samples still warrants further studies.https://doi.org/10.1111/1759-7714.14075Core needle biopsyEBBEBUS‐TBNAimmune checkpoint inhibitorPD‐L1 expression |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Minjiang Chen Yan Xu Jing Zhao Ji Li Xiangning Liu Wei Zhong Mengzhao Wang |
spellingShingle |
Minjiang Chen Yan Xu Jing Zhao Ji Li Xiangning Liu Wei Zhong Mengzhao Wang Feasibility and reliability of evaluate PD‐L1 expression determination using small biopsy specimens in non‐small cell lung cancer Thoracic Cancer Core needle biopsy EBB EBUS‐TBNA immune checkpoint inhibitor PD‐L1 expression |
author_facet |
Minjiang Chen Yan Xu Jing Zhao Ji Li Xiangning Liu Wei Zhong Mengzhao Wang |
author_sort |
Minjiang Chen |
title |
Feasibility and reliability of evaluate PD‐L1 expression determination using small biopsy specimens in non‐small cell lung cancer |
title_short |
Feasibility and reliability of evaluate PD‐L1 expression determination using small biopsy specimens in non‐small cell lung cancer |
title_full |
Feasibility and reliability of evaluate PD‐L1 expression determination using small biopsy specimens in non‐small cell lung cancer |
title_fullStr |
Feasibility and reliability of evaluate PD‐L1 expression determination using small biopsy specimens in non‐small cell lung cancer |
title_full_unstemmed |
Feasibility and reliability of evaluate PD‐L1 expression determination using small biopsy specimens in non‐small cell lung cancer |
title_sort |
feasibility and reliability of evaluate pd‐l1 expression determination using small biopsy specimens in non‐small cell lung cancer |
publisher |
Wiley |
series |
Thoracic Cancer |
issn |
1759-7706 1759-7714 |
publishDate |
2021-09-01 |
description |
Abstract Background Programmed cell death ligand‐1 (PD‐L1) is a useful biomarker in non‐small cell lung cancer (NSCLC) patients who would probably benefit from immunotherapy. In most patients with advanced stage NSCLC, only small biopsy specimens were available for the evaluation of PD‐L1 expression. In this study, we evaluated the feasibility and reliability of PD‐L1 testing on small biopsy samples. Methods Small specimens of advanced NSCLC patients obtained via endobronchial ultrasound‐guided transbronchial needle aspiration (EBUS‐TBNA), endobronchial biopsy (EBB), or computed tomography (CT)‐guided core‐needle biopsy were collected. Tumor cell count and tissue sufficiency for PD‐L1 immunohistochemistry (IHC) were evaluated and compared. The clinical course of patients who received immunotherapy in the study population was also examined. Results Tissue acquisitions for PD‐L1 testing in three groups were all above 90%, with no statistically significant differences. The PD‐L1 expressions levels were concordant in most patients with more than one sample (8/11). In the EBB group, PD‐L1‐positive patients had higher objective response rate (ORR) (53.2% vs. 26.9%, p = 0.048) and longer progression‐free survival (PFS) (312 vs. 179 days, p = 0.035) than PD‐L1 negative patients. In the core needle biopsy group, patients with positive PD‐L1 expression also trended to have higher ORR and longer PFS. However, in the EBUS‐TBNA group, both ORR and PFS were similar between patients with positive or negative PD‐L1 expression. Conclusions This study showed that EBUS‐TBNA, EBB, and core needle biopsy provides adequate samples for PD‐L1 testing. The predictive value of PD‐L1 expression on different small samples still warrants further studies. |
topic |
Core needle biopsy EBB EBUS‐TBNA immune checkpoint inhibitor PD‐L1 expression |
url |
https://doi.org/10.1111/1759-7714.14075 |
work_keys_str_mv |
AT minjiangchen feasibilityandreliabilityofevaluatepdl1expressiondeterminationusingsmallbiopsyspecimensinnonsmallcelllungcancer AT yanxu feasibilityandreliabilityofevaluatepdl1expressiondeterminationusingsmallbiopsyspecimensinnonsmallcelllungcancer AT jingzhao feasibilityandreliabilityofevaluatepdl1expressiondeterminationusingsmallbiopsyspecimensinnonsmallcelllungcancer AT jili feasibilityandreliabilityofevaluatepdl1expressiondeterminationusingsmallbiopsyspecimensinnonsmallcelllungcancer AT xiangningliu feasibilityandreliabilityofevaluatepdl1expressiondeterminationusingsmallbiopsyspecimensinnonsmallcelllungcancer AT weizhong feasibilityandreliabilityofevaluatepdl1expressiondeterminationusingsmallbiopsyspecimensinnonsmallcelllungcancer AT mengzhaowang feasibilityandreliabilityofevaluatepdl1expressiondeterminationusingsmallbiopsyspecimensinnonsmallcelllungcancer |
_version_ |
1724162931725172736 |